279489
Identifying adverse drug events after discharge from a community hospital
Methods: Adverse drug events are defined as medication related injuries occurring as a result of medical management. Patients were recruited prospectively prior to discharge from a hospitalist service of a community hospital. Postdischarge adverse drug events were determined by performing an independent implicit health record review (both inpatient and outpatient) and a structured telephone interview approximately 3-weeks after discharge from the hospital. We provide frequencies and an odds ratio with 95% confidence intervals (CI) to estimate the likelihood of rural patients experiencing a postdischarge adverse drug event when compared to urban patients.
Results: Health record reviews and telephone interviews were completed for 406 patients. One hundred ninety-eight (48.8%) were rural patients and 208 (51.2%) were urban patients. Fifty-six (13.8%) of 406 patients experienced postdischarge adverse drug events. Of these, 26 (46.4%) were rural patients and 30 (53.6%) were urban patients. The odds ratio was 0.91 (95% CI: 0.46-1.82) for rural patients experiencing a postdischarge adverse drug event when compared to urban patients.
Conclusion: Preliminary results do not indicate statistically significant differences for experiencing postdischarge adverse drug events when comparing rural with urban patients. We expect to have completed health record reviews and telephone interviews for 608 patients by November 2013.
Public health or related research
Learning Objectives:
Define adverse events related to medication injury after discharge from the hospital.
Compare the frequency of post-discharge adverse drug events in rural and urban patients.
Keywords: Injury, Quality of Care
Qualified on the content I am responsible for because: I have several publications on postdischarge adverse events and was recently awarded an R01 grant from AHRQ to investigate postdischarge adverse events.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.